A Prospective Study of Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Carcinoma
- Sponsor
- Peking University People's Hospital
- Enrollment
- 45
- Primary Endpoint
- The detection rate of cancer related genes in multiple primary lung cancer patients by targeted next generation sequencing
- Last Updated
- 6 years ago
Overview
Brief Summary
Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate the feasibility and application value by using NGS into identifying genomic mutations in multiple or multifocal primary lung cancers in cell-tumor DNA (ctDNA) from surgical patients
Detailed Description
Tumor samples originating from clinically considered multiple or multifocal primary lung cancer patients were available for mutational analysis. DNA and RNA were extracted from fresh tumor tissue or formalin-fixed, paraffin-embedded (FFPE) tissue. A series of cancer-related genomic alterations including single nucleotide variations (SNVs), short insertions and deletions (InDels), copy number variations (CNVs) and gene rearrangements were identified by a comprehensive NGS Panal . High frequency mutations were also identified in blood sample by droplet digital polymerase chain reaction(ddPCR).
Investigators
Chen KeZhong
MD，Thoracic Surgery Service
Peking University People's Hospital
Eligibility Criteria
Inclusion Criteria
- •Patients must have given written informed consent
- •Histopathologically confirmed NSCLC
- •Considered multiple or multifocal primary lung cancer by clinical criteria
Exclusion Criteria
- •Malignant tumor history within the past 5 years
- •Patients who received any treatment prior to resection
- •Insufficient tumor tissue or blood sample
Outcomes
Primary Outcomes
The detection rate of cancer related genes in multiple primary lung cancer patients by targeted next generation sequencing
Time Frame: 18 months
Secondary Outcomes
- The concordant and discordant frequency of genomic results between tumor tissue and circulating tumor DNA in multiple primary lung cancer patients(18 months)
- The relationship between overall survival and genomic results in multiple primary lung cancer patients(5 years)
- The relationship between disease free survival and genomic results in multiple primary lung cancer patients(5 years)